Last update 04 Nov 2024
Tianjin Hengrui Pharmaceutical Co., Ltd
Private Company | Subsidiary Company|
2020|
Tianjin Shi, China
Last update 04 Nov 2024
Overview
Basic Info
Introduction Tianjin Hengrui Pharmaceuticals Co., Ltd. operates as a wholly-owned subsidiary of Hengrui Medicine, founded in November 2020. Its mission is to build an integrated platform dedicated to the research and development transformation of oncology diagnostic and therapeutic drugs. |
Tags
Neoplasms
Urogenital Diseases
Digestive System Disorders
Small molecule drug
Diagnostic radiopharmaceuticals
Therapeutic radiopharmaceuticals
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
镓[68Ga]伊索曲肽用于生长抑素受体过表达的高分化胃肠胰神经内分泌瘤 PET/CT 诊断的前瞻性、单臂、盲态阅片、自身对照 III 期临床研究
[Translation] A prospective, single-arm, blinded, self-controlled phase III clinical study of gallium [68Ga] esotreotide for the PET/CT diagnosis of well-differentiated gastroenteropancreatic neuroendocrine tumors with somatostatin receptor overexpression
评价HRS-9815用于前列腺癌患者PET/CT成像的安全性、药代动力学及辐射剂量学I期临床研究
[Translation] Phase I clinical study to evaluate the safety, pharmacokinetics and radiation dosimetry of HRS-9815 for PET/CT imaging in patients with prostate cancer
HRS-4357用于PSMA阳性晚期前列腺癌患者治疗的药代动力学及辐射剂量学、安全性及初步有效性评价的I/II期临床研究
[Translation] A Phase I/II clinical study of HRS-4357 for the treatment of patients with PSMA-positive advanced prostate cancer: pharmacokinetics, radiation dosimetry, safety, and preliminary efficacy evaluation
100 Clinical Results associated with Tianjin Hengrui Pharmaceutical Co., Ltd
Login to view more data
Login to view more data
100 Deals associated with Tianjin Hengrui Pharmaceutical Co., Ltd
Login to view more data
100 Translational Medicine associated with Tianjin Hengrui Pharmaceutical Co., Ltd
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 23 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
1
Phase 1
Phase 2
1
1
Phase 3
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free